Argos Therapeutics, Inc. is developing fully personalized immunotherapies that target unique features of a patient’s disease. This new generation of personalized therapeutics trains the immune system to recognize and attack diseases. Argos’ scientific leadership in RNA-loaded dendritic cells and advanced manufacturing processes provide a platform that we believe can tackle a wide range of cancers and infectious diseases.
Argos Therapeutics Reports First Quarter 2016 Financial Results and Operational Highlights
Argos Therapeutics to Participate in World Stem Cells and Regenerative Medicine Congress
Argos Therapeutics to Host First Quarter 2016 Financial Results Conference Call on Thursday, May 12, 2016